Mesothelioma and Thymic Tumors

  • Fred Y. Wu
  • Brian Lee
  • Joycelyn L. Speight


Rare: only 2,000–3,000 cases per year in the US. Eighty percent cases involve asbestos exposure. Strong causal relationship exists with cigarette smoking. Can affect visceral pleura, parietal pleura, and peritoneum. May mimic adenocarcinoma on pathologic examination; immunohistochemical staining required for definitive diagnosis.


Malignant Pleural Mesothelioma Radiation Pneumonitis Thymic Carcinoma Helical Tomotherapy Lung Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006;65(3):640-645.PubMedCrossRefGoogle Scholar
  2. Allen AM, Den R, Wong JS, et al. Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys. 2007;68(5):1366-1374.PubMedCrossRefGoogle Scholar
  3. Allen AM, Schoenfield MS, Hacker F et al. Restricted field IMRT dramatically enhances IMRT planning for mesothelioma. Int J Radiat Oncol Biol Phys. 2007;69(5):1587-1592.PubMedCrossRefGoogle Scholar
  4. Batata M. Thymomas: Clinicopathologic features, therapy, and prognosis. Cancer 1974;34:389-396.PubMedCrossRefGoogle Scholar
  5. Berghmans T, Lafitte J, Paesmans M et al. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer 2005;50:75-82.PubMedCrossRefGoogle Scholar
  6. Boutin C, Rey F, Viallat R et al. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995;108(3):754-758.Google Scholar
  7. Bruin M, Burgers J, Baas P, et al. Malignant mesothelioma following radiation treatment for Hodgin’s lymphoma. Blood 2009;113(16):3679-3681.PubMedCrossRefGoogle Scholar
  8. Ceresoli G, Zucali P, Favaretto A, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24:1443-1448.PubMedCrossRefGoogle Scholar
  9. Ciernik IF, Meier U, Lutolf UM. Prognostic factors and outcome of incompletely resected invasive thymoma following radiation therapy. J Clin Oncol. 1994;12:1484-1490.PubMedGoogle Scholar
  10. Curran WJ Jr., Kornstein MJ, Brooks JJ, et al. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol. 1988;6:1722-1727.PubMedGoogle Scholar
  11. Eng TY, et al. Mediastinum and Trachea. In: Perez CA, Brady LW, Halperin ED, Schmidt-Ullrich RK, editors. Principles and practice of radiation oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. pp 1244-1281.Google Scholar
  12. Flores R, Krug L, Rosenzweig K, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a Phase II trial. J Thorac Oncol. 2006;1:289-295.PubMedCrossRefGoogle Scholar
  13. Forquer JA, Rong N, Fakiris AJ, et al. Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. Int J Radiat Oncol Biol Phys. 2010;76(2):440-445.PubMedCrossRefGoogle Scholar
  14. Hillerdal G, Sorensen J, Sundstrom S, et al. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol. 2008;3:1325-1331.PubMedCrossRefGoogle Scholar
  15. Janne P, Simon G, Langer C, et al. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naïve malignant pleural mesothelioma. J Clin Oncol. 2008;26:1465-1471.PubMedCrossRefGoogle Scholar
  16. Kalmadi S, Rankin C, Kraut M, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008;60:259-263.PubMedCrossRefGoogle Scholar
  17. Kim E, Putnam J, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004;44:369-379.PubMedCrossRefGoogle Scholar
  18. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 2003;76(3):878-884.PubMedCrossRefGoogle Scholar
  19. Krayenbuhl J, OErtel S, Davis JB, et al. Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumectomy. Int J Radiat Oncol Biol Phys. 2007;69(5):1593-1599.CrossRefGoogle Scholar
  20. Komaki R, Travis EL, Cox JD. The Lung and Thymus. In: Cox JD, Ang KK, editors. Radiation oncology: rationale, technique, results. 8th ed. St. Louis: Mosby; 2003. pp. 399-427.Google Scholar
  21. Loehrer Sr P, Wang W, Johnson D, et al. Octreotide alone or with prednisone in patient with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II trail. J Clin Oncol. 2004;22:293-299.PubMedCrossRefGoogle Scholar
  22. Lu C, Perez-Soler R, Piperdi B, et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol. 2005;23:3495-3501.PubMedCrossRefGoogle Scholar
  23. Lucchi M, Chella A, Dini P, et al. Four-modality therapy in malignant pleural mesothelioma: a phase II study. J Thorac Oncol. 2008;2:237-242.CrossRefGoogle Scholar
  24. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485.PubMedCrossRefGoogle Scholar
  25. Miles EF, Larrier NA, Kelsey CR, et al. Intensity modulated radiotherapy for restricted mesothelioma: the Duke Experience. Int J Radiat Oncol Biol Phys. 2008;71(4):1143-1150.PubMedCrossRefGoogle Scholar
  26. Monden Y, Nakahara K, Iioka S, et al. Recurrence of thymoma: clinicopathological features, therapy, and prognosis. Ann Thorac Surg. 1985;39:165-169.PubMedCrossRefGoogle Scholar
  27. Mornex F. Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. Int J Radiation Oncology Biol Phys. 1995;2:651-659.CrossRefGoogle Scholar
  28. Ohara K, Okumura T, Sugahara S, et al. The role of preoperative radiotherapy for invasive thymoma. Acta Oncol. 1990;29:425-429.PubMedCrossRefGoogle Scholar
  29. Okuno S, Delaune, Sloan J, et al. A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma. Cancer 2008;112:1772-1779.Google Scholar
  30. O’Rourke N, Garcia JC, Paul J et al. A randomized controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007;84(1):18-22.PubMedCrossRefGoogle Scholar
  31. Palmieri G, Montella L, Martignetti A, et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 2002;94:1414-1420.PubMedCrossRefGoogle Scholar
  32. Perrot M, Feld R, Cho B, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(9):1413-1418.PubMedCrossRefGoogle Scholar
  33. Plathow C, Staab A, Schmaehl A, et al. Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results. Invest Radiol. 2008;43:737-744.PubMedCrossRefGoogle Scholar
  34. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007;84(5):1685-1692.PubMedCrossRefGoogle Scholar
  35. Rosenzweig KE KL. Tumors of the Lung, Pleura, and Mediastinum. In Leibel SA, Phillips TL, editors. Textbook of radiation oncology. 2nd ed. Philadelphia: Saunders; 2004. pp. 779-810.Google Scholar
  36. Rosenzweig K, Fox J, Zelefsky M, et al. A pilot trial of high-dose-rate intraoperative radiation therapy for malignant pleural mesothelioma. Brachytherapy 2005;4:30-33.PubMedCrossRefGoogle Scholar
  37. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788-795.PubMedCrossRefGoogle Scholar
  38. Scagliotti G, Shin D, Kindler H, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003;21:1556-1561.PubMedCrossRefGoogle Scholar
  39. Sterzing F, Sroka-Perez G, Schubert K, et al. Evaluating taget coverage and normal tissue sparing in the adjuvant radiotherapy of malignant pleural mesothelioma: helical tomotherapy compared with step and shoot IMRT. Radiother Oncol. 2008;86(2):251-257.PubMedCrossRefGoogle Scholar
  40. Urgesi A, Monetti U, Rossi G, et al. Role of radiation therapy in locally advanced thymoma. Radiother Oncol. 1990;19:273-280.PubMedCrossRefGoogle Scholar
  41. van Meerbeeck JP, Baas P, Debruyne C, et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999;85:2577-2582.Google Scholar
  42. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-2644.PubMedCrossRefGoogle Scholar
  43. Wright CD, Choi NC, Wain JC, et al Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thoracic Surg. 2008;85(2):385-389.CrossRefGoogle Scholar
  44. Zhu G, He S, Fu X, et al. Radiotherapy and prognostic factors for thymoma: a retrospective study of 175 patients. Int J Radiat Oncol Biol Phys. 2004;60(4):1113-1119.PubMedCrossRefGoogle Scholar
  45. Zucali P, Ceresoli G, Garassino I, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008;112:1555-1561.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York 2010

Authors and Affiliations

  • Fred Y. Wu
    • 1
  • Brian Lee
    • 2
  • Joycelyn L. Speight
    • 3
  1. 1.Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Radiation OncologySwedish HospitalSeattleUSA
  3. 3.Board Certified Radiation OncologistSan FranciscoUSA

Personalised recommendations